CoChat

Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

Woodcock, Janet, Sharfstein, Joshua M., Hamburg, Margaret · 2010 · New England Journal of Medicine
Cited by 146

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

There have been ongoing concerns about the safety of the diabetes drugs containing rosiglitazone (Avandia, Avandaryl, and Avandamet) — a thiazolidinedione antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In 2007, a meta-analysis of controlled clinical trials found increases in the risk of myocardial infarction and a near-significant increased risk of death from cardiovascular causes when rosiglitazone was compared with placebo or with standard diabetes drugs.1 Following an advisory committee meeting held in July 2007, the U.S. Food and Drug Administration (FDA) added information about the possibility . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmp1010788

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 1

  1. 10.1016/S0140-6736(09)60953-3 · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Woodcock, J., Sharfstein, J. M., & Hamburg, M.
Venue
New England Journal of Medicine
Published
2010-10-14
Volume
363
Issue
16
Pages
1489-1491
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1975777549
Cited by
146
References
2
FWCI
17.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. https://app.cochat.ai/papers/10.1056/nejmp1010788
The paper
Woodcock, J., Sharfstein, J. M., & Hamburg, M. (2010). Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. New England Journal of Medicine. https://doi.org/10.1056/nejmp1010788

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.